GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
Signage for GlaxoSmithKline is seen on it's offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline is likely to escape generic ...
GSK would continue to make Advair inhalers in Zebulon if generic competition emerges this year. It also makes new asthma inhalers and two HIV drugs at its Zebulon facility. Chris Seward ...
Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...
Lannett has entered into an exclusive U.S. distribution agreement for Respirent’s generic Advair Diskus (fluticasone propionate – salmeterol xinafoate powder inhaler), which is still pending approval ...
GlaxoSmithKline’s Andrew Witty has spent his entire CEO stint fending off concerns about the arrival of generic Advair. But on his final quarterly conference call as helmsman, he finally laid out just ...
Sharon Bassett tries to stretch a month’s supply of GlaxoSmithKline Plc’s Advair over 60 days to save money on the asthma treatment because the U.S. lacks a cheaper generic version. An alternative ...
LONDON (Reuters) - GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data ...
Novartis’ triple combination asthma candidate QVM149 has beaten GlaxoSmithKline’s Advair in a phase 2 trial. The study linked QVM149 to statistically significant improvements in lung function, leading ...
LONDON, Sept 22 (Reuters) - GlaxoSmithKline gave a promising glimpse on Wednesday of a planned once-daily successor to its blockbuster lung treatment Advair, with results from a small study showing it ...
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and previous ...
LONDON (Reuters) - GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results